Guardant Health Inc (GH)

$98.36 -7.79 (-7.34%)
Market Cap 14.25B
Revenue (ttm) 739.02M
Net Income (ttm) -436.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -59.05%
Debt to Equity Ratio -3.14
Volume 5,320,100
Avg Vol 1,968,014
Day's Range N/A - N/A
Shares Out 126.04M
Stochastic %K 25%
Beta 1.63
Analysts Strong Sell
Price Target $128.33

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-pow...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 698 8887
Fax: 888 974 4258
Address:
3100 Hanover Street, Palo Alto, United States
Leondog1992
Leondog1992 Feb. 5 at 8:37 PM
$GH straight up giving me backshots
1 · Reply
MichaelDV
MichaelDV Feb. 5 at 6:36 PM
$GH Quiet consolidation, but this could squeeze higher if volume picks up
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 5:09 PM
$GH
0 · Reply
Gator5326
Gator5326 Feb. 5 at 4:20 PM
$GH WTF happened?
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 4:18 PM
$GH 50 shares at 103.89 avg
0 · Reply
IN0V8
IN0V8 Feb. 5 at 3:58 PM
$GH Bought at $102.20
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 3:29 PM
$GH
0 · Reply
GoldenBum77
GoldenBum77 Feb. 5 at 1:38 AM
$GH WAY undervalue. Super
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 4 at 11:10 PM
$GH Share Price: $106.23 Contract Selected: Jul 17, 2026 $105 Calls Buy Zone: $14.28 – $17.64 Target Zone: $22.75 – $27.81 Potential Upside: 50% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Leondog1992
Leondog1992 Feb. 4 at 8:23 PM
$GH
0 · Reply
Latest News on GH
Guardant Health to Participate in Upcoming Investor Conferences

Feb 3, 2026, 4:05 PM EST - 2 days ago

Guardant Health to Participate in Upcoming Investor Conferences

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Feb 2, 2026, 8:05 AM EST - 3 days ago

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Jan 29, 2026, 4:05 PM EST - 7 days ago

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Jan 29, 2026, 1:22 PM EST - 7 days ago

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

EXAS NBIS NTRA QURE STVN

Guardant Health: Look For Explosive Revenue Growth Ahead

Jan 26, 2026, 9:31 AM EST - 10 days ago

Guardant Health: Look For Explosive Revenue Growth Ahead

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

Jan 26, 2026, 3:54 AM EST - 10 days ago

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

EXAS NBIS NTRA RZLT WIX

Artisan Small Cap Fund Q4 2025 Portfolio Activity

Jan 23, 2026, 9:08 AM EST - 13 days ago

Artisan Small Cap Fund Q4 2025 Portfolio Activity

BRKR CLBT FLEX HXL INSM IRTC ITGR

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

Jan 22, 2026, 12:51 PM EST - 14 days ago

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Jan 22, 2026, 8:05 AM EST - 14 days ago

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

Jan 22, 2026, 5:15 AM EST - 14 days ago

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

EXAS HOOD NBIS NTRA RBLX

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Jan 19, 2026, 8:05 AM EST - 17 days ago

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Jan 18, 2026, 4:32 AM EST - 18 days ago

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 10:15 PM EST - 23 days ago

Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 11, 2026, 5:00 PM EST - 25 days ago

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Jan 8, 2026, 8:05 AM EST - 4 weeks ago

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:05 PM EST - 5 weeks ago

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening

Dec 29, 2025, 10:10 AM EST - 5 weeks ago

Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening

Where To Invest In 2026: Top 5 Secular Growth Trends

Dec 24, 2025, 8:30 AM EST - 6 weeks ago

Where To Invest In 2026: Top 5 Secular Growth Trends

AMPX CHYM LSCC MOD PRCT

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Dec 11, 2025, 8:05 AM EST - 2 months ago

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Dec 9, 2025, 8:05 AM EST - 2 months ago

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 8:05 AM EST - 2 months ago

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025

Dec 2, 2025, 7:23 PM EST - 2 months ago

Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025

HSY KO

5 Top Stocks For AI Fatigue

Nov 28, 2025, 11:47 AM EST - 2 months ago

5 Top Stocks For AI Fatigue

AMBP GSL OHI PARR

These 15 stocks are still showing momentum — and a market-beating edge

Nov 20, 2025, 3:45 PM EST - 2 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO INSM LITE MP MU

6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 2 months ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN MEDP WGS

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Nov 12, 2025, 8:05 AM EST - 3 months ago

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Nov 10, 2025, 8:05 AM EST - 3 months ago

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 6:35 PM EST - 3 months ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Nov 6, 2025, 8:05 AM EST - 3 months ago

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Nov 5, 2025, 4:05 PM EST - 3 months ago

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Nov 5, 2025, 2:15 AM EST - 3 months ago

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Nov 5, 2025, 2:15 AM EST - 3 months ago

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Guardant Health Announces Proposed Public Offering of Common Stock

Nov 4, 2025, 4:39 PM EST - 3 months ago

Guardant Health Announces Proposed Public Offering of Common Stock

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Nov 4, 2025, 4:38 PM EST - 3 months ago

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts

Oct 31, 2025, 11:09 AM EDT - 3 months ago

Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts

Guardant Health: Business Continues To Gather Pace

Oct 30, 2025, 9:03 PM EDT - 3 months ago

Guardant Health: Business Continues To Gather Pace

Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 1:46 AM EDT - 3 months ago

Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Oct 27, 2025, 8:05 AM EDT - 3 months ago

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Oct 26, 2025, 3:01 PM EDT - 3 months ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Oct 15, 2025, 4:57 PM EDT - 4 months ago

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

Oct 9, 2025, 4:05 PM EDT - 4 months ago

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Sep 29, 2025, 8:05 AM EDT - 4 months ago

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Guardant Health, Inc. (GH) Analyst/Investor Day Transcript

Sep 24, 2025, 7:17 PM EDT - 4 months ago

Guardant Health, Inc. (GH) Analyst/Investor Day Transcript

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

Sep 24, 2025, 8:05 AM EDT - 4 months ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

DGX

Alex M. Azar II Joins Guardant Health Board of Directors

Sep 15, 2025, 4:07 PM EDT - 5 months ago

Alex M. Azar II Joins Guardant Health Board of Directors

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Sep 11, 2025, 8:05 AM EDT - 5 months ago

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 6:56 PM EDT - 5 months ago

Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Sep 8, 2025, 8:05 AM EDT - 5 months ago

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Sep 4, 2025, 8:06 AM EDT - 5 months ago

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Leondog1992
Leondog1992 Feb. 5 at 8:37 PM
$GH straight up giving me backshots
1 · Reply
MichaelDV
MichaelDV Feb. 5 at 6:36 PM
$GH Quiet consolidation, but this could squeeze higher if volume picks up
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 5:09 PM
$GH
0 · Reply
Gator5326
Gator5326 Feb. 5 at 4:20 PM
$GH WTF happened?
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 4:18 PM
$GH 50 shares at 103.89 avg
0 · Reply
IN0V8
IN0V8 Feb. 5 at 3:58 PM
$GH Bought at $102.20
0 · Reply
Leondog1992
Leondog1992 Feb. 5 at 3:29 PM
$GH
0 · Reply
GoldenBum77
GoldenBum77 Feb. 5 at 1:38 AM
$GH WAY undervalue. Super
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 4 at 11:10 PM
$GH Share Price: $106.23 Contract Selected: Jul 17, 2026 $105 Calls Buy Zone: $14.28 – $17.64 Target Zone: $22.75 – $27.81 Potential Upside: 50% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Leondog1992
Leondog1992 Feb. 4 at 8:23 PM
$GH
0 · Reply
JasonCO
JasonCO Feb. 2 at 4:43 PM
$GH
0 · Reply
Gator5326
Gator5326 Feb. 2 at 2:30 PM
$GH it just gets better and better https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyeeyXFUZ2-2BizumqqQrksYe-2F0qSgtyuJaPkE3rtC1R1xMY2joUedjpGyFHnb2IO6pwa-2FpqGOVCAj5g5f72O6w9xX7pXp6MHFOEF8z42XKP5PicVB8Z7kiTAhIljVxQYD9hIIyHMikY-2BEn5anv6yRFrVdzTeLpKo9PCaY67uUNZgDSxMOFlsJF2UL0AzxH-2F3HSua398hQKoaOCmHZHrIIKvBCrlWNRUAY-2BhlDgwHO8KEdhBaOl5zrjuv3LYeCCxzkkXmsSTcT1oSGhhNSXtS1-2BxuxDp9xspWriyJYsojncDof2f0JHuoAsD6X-2BHtHzzzVU5k-3DByFD_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHa14Dzo4qi92-2BXBJfNleK5VkgJnExQpnpWYMGpvJ0CrGBVF5XAxiMOHEGfTyluvOkRmmPVIdxk7r6guYJcFdFf8q73WvvPk8j09dStkLYeW-2BIKjqW92EqHaQtE7u63ZN08Xtwy-2BtMhY4-2Bl0JZaeKTCoD5RU2dvro4JAzJ-2BnMMUiK2RD-2FixjAgfuHXE0fOb7MnzO5BWsONHT-2FHuYjajuwCVrYPVXfT-2Bv5rAjczWNDVveGr1UubJEwOSJ3Wkm5kIMYm42m-2F7nYIOT69uTf36sdq08Flh0kTmKGVk8ivmoZsNsh687WrXKlIrb6cAmi3DwCRX6743-2F0INhkDSH0vpN0Y2TGk8oPfjgPU9mo1tNrYsen8PnRVJ9f0kWZPmxfBJv5ZLNT-2FqWA1jl0jocgiqqNwN7cTPjl408fL1ADZiMlPuBlnFTPlLgvKucom2cGEorQpivNdoDAHGrN86zTiM0uw5A-3D-3D
0 · Reply
Honeystocks
Honeystocks Feb. 2 at 12:24 AM
(ICYMI) - THE FEBRUARY OUTLOOK FOR US STOCKS. Futures are now open, so what are the charts signalling for February? $XLE $DBC $LMND $GH and old fav $ZM also moving plus another 20 stocks for your February watchlists. 👇 https://www.honeystocks.com/analysis
0 · Reply
Honeystocks
Honeystocks Jan. 31 at 2:29 PM
THE FEBRUARY OUTLOOK FOR US STOCKS. January was a great month for stock pickers but what are the charts signalling for February? $XLE $DBC $LMND $GH and old fav $ZM also moving plus another 20 stocks for your February watchlists. 👇 https://www.honeystocks.com/analysis
0 · Reply
JFDI
JFDI Jan. 30 at 6:58 PM
$GH major RS
1 · Reply
JasonCO
JasonCO Jan. 30 at 2:35 PM
$GH
0 · Reply
RunnerSignals
RunnerSignals Jan. 29 at 8:46 PM
$GH 5 down days and buyers stepped in late. needs catalyst
1 · Reply
Leondog1992
Leondog1992 Jan. 29 at 7:04 PM
$FROG $GH $GMED $IRTC $RKT Just remember money and this life is only Temporary. Jesus is king
1 · Reply
Leondog1992
Leondog1992 Jan. 29 at 4:43 PM
$FROG $RKT $GH $IRTC $GMED
1 · Reply
Bom_Jesus
Bom_Jesus Jan. 29 at 2:58 PM
$GH
0 · Reply
Leondog1992
Leondog1992 Jan. 29 at 2:50 PM
$GH
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 1:21 AM
$GH Share Price: $109.72 Contract Selected: Jul 17, 2026 $110 Calls Buy Zone: $14.11 – $17.43 Target Zone: $24.62 – $30.10 Potential Upside: 65% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply